KAI PHARMACEUTICALS
KAI Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of cardiovascular disease, kidney disease and pain. KAI lead product candidate, KAI-9803, is currently in a Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attack patients. KAI second core program, KAI-4169 for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients, is expected to enter human clinical trials in 2010. KAI also has an ongoing pain program, KAI-1678, which is currently in Phase 2a testing.
KAI PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Medical Therapeutics
Founded:
2002-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.kaipharmaceuticals.com
Total Employee:
10001+
Status:
Active
Contact:
650-244-1100
Email Addresses:
[email protected]
Total Funding:
52 M USD
Technology used in webpage:
SPF Amazon Amazon Ohio Region NameBright
Similar Organizations
Cahaba Pharmaceuticals
Cahaba Pharmaceuticals develops novel therapeutics and supportive care products for cancer patients.
Galenea
Galenea is engaged in developing therapeutics for central nervous system diseases.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Sight Pharma Inc.
Sight Pharma develops novel therapies for oncology and cardiovascular diseases in collaboration with universities.
Current Advisors List
Current Employees Featured
Founder
Investors List
Skyline Ventures
Skyline Ventures investment in Series B - KAI Pharmaceuticals
InterWest Partners
InterWest Partners investment in Series B - KAI Pharmaceuticals
Intersouth Partners
Intersouth Partners investment in Series B - KAI Pharmaceuticals
Aberdare Ventures
Aberdare Ventures investment in Series B - KAI Pharmaceuticals
Investor Growth Capital Limited
Investor Growth Capital Limited investment in Series B - KAI Pharmaceuticals
MDS Capital
MDS Capital investment in Series B - KAI Pharmaceuticals
Delphi Ventures
Delphi Ventures investment in Series B - KAI Pharmaceuticals
Intersouth Partners
Intersouth Partners investment in Series A - KAI Pharmaceuticals
Skyline Ventures
Skyline Ventures investment in Series A - KAI Pharmaceuticals
InterWest Partners
InterWest Partners investment in Series A - KAI Pharmaceuticals
Official Site Inspections
http://www.kaipharmaceuticals.com
- Host name: ec2-54-243-117-197.compute-1.amazonaws.com
- IP address: 54.243.117.197
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
